GGrantIndex
← Search

PROGRAM 6 (CANCER RISK AND PREVENTION)

$32,277P30FY2012CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

The Cancer Risk and Prevention Program (Program 6) is an extremely interdisciplinary program involving 32 members from 11 Departments representing basic, translational, and clinical investigators. Members have a total of $ 7,327,303 in peer-reviewed funding, including $1,403,749 from the NCI. Over the past grant cycle, Program 6 members generated a total of 269 peer-reviewed publications, including 8% intraprogrammatic, and 25% interprogrammatic publications. The overall objectives of the Cancer Risk and Prevention Program are to understand the genetic, psychological, behavioral, and socio-environmental basis of cancer and to disseminate cancer control efforts through research in our local community. The specific scientific goals are (1) to elucidate the genetic and environmental basis, as well as the mechanisms of progression, for common cancers (breast, ovarian, colorectal, prostate, lung, skin, and blood), and to translate this new knowledge into clinical and public health practice; (2) to develop animal models for chemoprevention studies and develop biomarkers for early detection of cancer; (3) to identify genetic, psychological, and bio-behavioral bases of cancer risk and prevention; and (4) to establish an organized outreach research effort in the Southside Chicago neighborhoods to enhance and empower their participation and utilization of University of Chicago research, educational and clinical services, thereby reducing the disparities in cancer and other health outcomes and their modifiable determinants in the community. The heterogeneity of research within the Program is a strength, but it also presents challenges, given the wide-ranging foci of scientific investigations from basic scientific research in carcinogenesis through preclinical and clinical translational research. Particular strengths of the Program include molecular epidemiology, basic and clinical studies in addiction and high-risk health behaviors, and studies of environmental toxicity and population-based genetics. This program encompasses transdisciplinary interactions and collaborations fostered by program-specific activities, by the close proximity of the investigators at the University of Chicago campus and, particularly, by the large collaborative research grants, such as the Center for Interdisciplinary Health Disparities Research, Breast Cancer SPORE, PO1s, and training grants within the Program.

View original record on NIH RePORTER →